KALA BIO Faces Nasdaq Delisting After 30 Days Below $1
KALA sits 35% above its 52-week low of $0.59 on light trading volume (0.2× avg).
Summary
KALA BIO received a Nasdaq delisting determination after its stock traded below $1.00 for 30 consecutive business days. The company is ineligible for the standard compliance period due to its May 2026 reverse stock split and must appeal to the Nasdaq Hearings Panel.
Key Events · Legal and Risk Events · KALA
-
Nasdaq Delisting Determination Received
On August 27, 2026, Nasdaq notified KALA BIO that its stock traded below $1.00 for 30 consecutive business days (July 16 – August 26, 2026), violating the minimum bid price requirement.
-
No Standard Compliance Period
KALA BIO is ineligible for the usual 180-day compliance period because it completed a 1-for-50 reverse stock split on May 11, 2026, within the prior one-year period.
-
Appeal to Nasdaq Hearings Panel
The company intends to request a hearing before the Nasdaq Hearings Panel, which would stay any suspension or delisting action pending the Panel's decision. No assurance the appeal will be granted.
-
Distress Context
This delisting notice follows a going-concern warning, a material weakness in internal controls, and cash under $0.1M disclosed in the Q2 10-Q filed August 19, 2026.
Analysis · KALA · Life Sciences
Nasdaq has determined KALA BIO is not in compliance with the minimum bid price requirement after the stock traded below $1.00 for 30 consecutive business days. Critically, the company is not eligible for the standard 180-day compliance period because it completed a 1-for-50 reverse stock split on May 11, 2026 — within the prior one-year period. This means the company must appeal to the Nasdaq Hearings Panel to avoid delisting, and there is no assurance the appeal will succeed. The stock currently trades at $0.795, below the $1.00 threshold. This comes amid a going-concern warning, a material weakness in internal controls, and cash under $0.1M disclosed in the Q2 10-Q filed August 19, 2026.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KALA was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $0.59 to $1,030.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.